Real-World Data for Integration Strategy of Radiotherapy (RT) With Immunotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)

Our real-world data supports that synergistic effective of RT can be achieved in combination with ICIs for metastatic NSCLC when RT was admitted with sequential fashion, ablative dose to one and non-bone metastatic site. Together with significant prognostic value of Post-RT NLR, it has been clearly demonstrated that the integration strategy of RT with ICIs should choose RT which would not compromise existing innate immunity of patients.